rHSC-DIPGVax

rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein (HSP) vaccine containing 16 peptides that reflect neo-epitopes found in the majority of diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) tumors. The vaccine is designed to stimulate the patient's immune system to recognize and attack tumor cells by presenting tumor-specific antigens. It is being investigated in combination with checkpoint inhibitors such as balstilimab (anti-PD-1 antibody) and zalifrelimab (anti-CTLA-4 antibody). The primary indication is for newly diagnosed pediatric patients with DIPG or DMG who have completed radiation therapy[2][3][6].